Author Details

Scroll

Refine your search

Collections

Medical Collection

Co-Authors

Journals

Indian Journal of Public Health Research & Development

Year

2012
2011

Authors

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

Anitha, M. R.

A Pilot Syudy of Relation of Polycystic Ovary Syndrome and Metabolic Disorder in Davangere, Karnataka

Abstract Views :341 | PDF Views:0

Authors

Geetha Hosanemati ¹, Gayatri Patil ¹, Prema Prabhudev ¹, M. R. Anitha ², V. Vijayanath ³, L. S. Patil ⁴

Affiliations
1 Department of Obstetrics and Gynaecology, S.S.Institute of Medical Sciences & Research Centre, Davangere-577005, Karnataka, IN
2 Department of Anatomy, S.S.Institute of Medical Sciences & Research Centre, Davangere-577005, Karnataka, IN
3 Department of Forensic Medicine & Toxicology, S.S.Institute of Medical Sciences & Research Centre, Davangere-577005, Karnataka, IN
4 Department of Surgical Oncology, S.S.Institute of Medical Sciences & Research Centre, Davangere-577005, Karnataka, IN

Source

Indian Journal of Public Health Research & Development, Vol 3, No 2 (2012), Pagination: 40-44

Abstract

Introduction

Polycystic ovarian syndrome (PCOS) is seen in 5 - 10% of women of the reproductive age, is the most common form of anovulatory infertility.

Evidence prove that these women exhibit a characteristic dyslipidaemia non insulin dependent diabetes and cardiovascular disease in later life, which are the hallmarks of the metabolic syndrome.

Presence of 3 of 5 common cardiovascular risk factors as a criteria, the prevalence of metabolic syndrome in PCOS is very high (43 - 46%).

Primary infertility cases with clinical features of menstrual irregularities, weight gain, hirsutism, acne and galactorrhea with scan picture of polycystic ovaries were considered for diagnosing PCOS cases.

Aim of the Study

Aim is to establish the relation between PCOS and metabolic syndrome.

Material and Methods

Study Design

A prospective, noninterventional case control study was conducted with 60 primary infertility patients, attending the gynaecological department, S.S. Institute of Medical Sciences and Research Centre, Davangere, Karnataka.

Study population

All these patients had clinical features suggestive of PCOS, of these 30 patients with ultrasound findings of polycystic ovaries were taken as cases and the others were age matched contemporary controls.

Age group: 20 - 30 years. Duration of study: 8 months. (Dec. 2009 - July 2010)

Methodology

After a brief history, waist circumference and blood pressure was recorded, then patients were asked to come on overnight fasting for a fasting blood sugar level and lipid profile assessment.

Results

In the present study all the five parameters needed for diagnosing metabolic syndrome were raised in PCOS cases and compared to controls. Values were statistically significant by student's unpaired 't' test.

An incidence of 38% of metabolic syndrome was noted in the PCOS cases studied.

Conclusion

Women with PCOS were strongly associated with metabolic syndrome when compared with the controls.

Obesity, high triglycerides and low high density lipoprotein levels are closely linked to insulin resistance and they are independent predictors of myocardial infarction and cardiovascular disease.

Results strongly indicate the need for comprehensive screening and education program for women of all ages with PCOS. Modification of lifestyle factors such as diet and exercise along with insulin sensitizers and lipid lowering agents can prevent long term health risks.

Full Text

References

Hull MGR. Epidemilogy of infertility and polycystic ovarian disease : endocrinological and demographic studies. Gynecol Endocrinol 1987;1(235-45).

Adams J, Polson DW, Franks S. Prevalenceof polycystic ovaries in women with anovulation and idiopathic hirsutism. Br Med J 1986;239:355-9.

Frank S. Polycystic ovary syndroem. N Engl J Med 1995;333:853- 861.

Glueck CJ, Papanna R, Wang P et al. Incidence and treatmetn of metabolic syndrome in newly referred women with confirmed polycystic ovary syndrome. Metabolism 2003;52:908-15.

Ford ES, Giles WH, Dietz WH. Prevalence of metabolic syndrome among us adults : findings from the third national health and trition examination survey. JAMA 2002;287:356-9.

Attaran Marjan. Polycystic ovary syndrome, cleveland clinicmeded 2004;1-8.

Conway G, Agarwal R, Betteridge DJ, Jacobs HS. Risk factors for coronary heart disease in lean and obese PCOS. Clin Endocrinol 1992;37:119-125.

Revised 2003 consensus on diagnostic criteria and long term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19-25.

Faloia E, Canibus P, Gatti C, Frezza F, et al. Body composition, fat distribution and metabolic characteristics in lean and obese women with polycystic ovary syndrome. J Endocrinol Invest 2004;27:424-9.

Dahlgren E, Janson PO, Johansson S. Polycystic ovary syndrome and risk for myocardial infarction evaluated for a risk factor model based on a prospective study of women. Acta Obstet Gynecol Scand 1992;71:599-604.

Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome : a prospective controlled study in 254 affected women. J Clin Endocrinol Metab 1999;84:165-9.

Gaziano JM, Hennekens CH, O’Donnell. Fasting triglycerides, high density lipoprotein and risk of myocardial infarction. Circulation 1997;96:2520-5.

Maruyama C, Imamura K, Teramato T. Assessment of LDL particle size by triglyceride / HDL cholesterol ratio in nondiabetic heatlhy subjects. J Atheroscler Thromb 2003;10:186-91.

McLaughlin T, Abbasi F, Cheal K, Chu J, et al. Use of metabolic markers identify overweight individuals who are insulin resistant. Ann Intern Med 2003;139:802-9.

Brehm A, Pfeiler G, et al. Relationship between serum lipopotein ratios and insulin resistance in obesity. Clin Chem 2004;54:2316-22.

Executive summary of the third report of the NECP, expert panel on detection, evaluation and treatment of high blood cholesterol in adults (ATP III). J Am Med Asso 2001;285:2486- 2497.

Barnard RJ, Wen SJ. Exercise and diet in the prevention and control of the metabolic syndrome. Sports Med 1994;18:218- 28.

Clinical Use and Safety of Medical Method of first Trimester Abortion

Abstract Views :212 | PDF Views:0

Authors

Geetha Hosanemati ¹, Gayatri Patil ¹, Prema Prabhudev ¹, M. R. Anitha ², V. Vijayanath ³, L. S. Patil ⁴

Source

Indian Journal of Public Health Research & Development, Vol 3, No 2 (2012), Pagination: 45-48

Abstract

Introduction

Women have a right to undergo an abortion if she wishes. Medical abortion is legally accepted under the Indian law. Mifepristone and misoprostol combination offers a safe, nonsurgical alternative for pregnancy termination with good success rates.

Aims and Objectives

The purpose of this study was to evaluation of the clinical efficacy of the combination of mifepristone and misoprostol orally for early termination of pregnancy.

Methods

A prospective clinical study conducted during a one year period included 100 healthy pregnant women consenting for a legal abortion with an ammenorrhoea of no more than 63 days.

Results

This method had a success rate of 94%, with an average induction abortion interval between 40-50 hours, one women needed surgical curettage. No serious side effects expect for nausea was noted.

Conclusion

The combination of mifepristone and misoprostol is effective for the termination of early pregnancy in terms of success, tolerance, safety and practicality.

Full Text

References

Manju MV. Jassawalla MJ. Manual ontermination of pregnancy, 3rd edn., 1999;9-11,55-59.

WHO : Pregnancy termination with mifepristone and semeprost – A multicentre comparison between repeated doses and a single dose of mifepristone; fertile steril; 1991:56:32-40.

Norman JE, Kelly RW, Glasler AF. Effects of Mifepristone in vivo on decidual prostaglandin synthesis and metabolism; contraception; 1991;49:88-89.

Usha K. Antiprogesterons, today and tomarrow, review article. J Obs Gynec 2000;26-34.

Wel SG et al. Termination of early pregnancy by two regimens of mifepristone with misoprostol and PGO5 – a multicentre randomized clinical trial in china; Contraception; 1994;50:501- 510.

Birgerson L, Odlind V. Early pregnancy termination with antiprogestins : a comparative clinical study of Ru 486 given in two dose regimens and epostane, Fertil Steril 1987;48(4):565- 70.

Remi P, Elisabeth A et al. Early termination of pregnancy with mifepristone and the orally active prostaglandin misoprostol, N Engl J Med 1993;328:1509-13.

Bahzad C, Wyssling H, Saraya, Yougen S. Termination of early human pregnancy with mifepristone and the prostaglandin analogue sulprostone; a multicentre randomized comparison between two treatment regimens; Oxford J Human Reprod 1989;4(6):718-725.

Beatrice C, LeNelly S, Andre U et al. Termination of early pregnancy by the progesterone antagonist Ru (486) Mifepristone, N Engl J Med, 1996;315:1565-1570.

UK Multicentre trial : The efficacy and tolerance of mifepristone and prostaglandin in first trimester termination of pregnancy, Br J Obstet Gynaecol; 1998;97:480-86.

Florence D, Catherine D, Joelle B, Rene F. Efficacy of progesterone antagonist Ru 486 (Mifepristone) for preoperative cervical dilatation during first trimester abortion, Oxford J Human Reproduct 1988;3(5):583-84.

Histomorphological Study of Malignant Tumours of Liver

Abstract Views :216 | PDF Views:0

Authors

P. Deepti ¹, S. S. Hiremath ¹, H. R. Chandrashekhra ¹, P. Shashikala ¹, M. R. Anitha ², V. Vijayanath ³

Affiliations
1 Department of Pathology, S.S.Institute of Medical Sciences & Research Centre, Davangere-577005, Karnataka, IN
2 Department of Anatomy, S.S.Institute of Medical Sciences & Research Centre, Davangere-577005, Karnataka, IN
3 Department of Forensic Medicine & Toxicology, S.S.Institute of Medical Sciences & Research Centre, Davangere-577005, Karnataka, IN

Source

Indian Journal of Public Health Research & Development, Vol 3, No 3 (2012), Pagination: 51-55

Abstract

No Abstract

Full Text

References

Crawford, J.M. “The liver and the biliary tract”. Chapter 19 in Robbins Pathologic basis of disease, Ed. 6, Edt. by Kumar Cotran Robins, Singapore, Har Court – Asia, 1999, 845-901pp.

Scheuer, P.J. “Neoplasms and nodules”, Chapter 11, Liver biopsy interpretation, Ed. 5, Edt. by Peter J. Scheur and Jay H Leekowitch, London, W.B. Saunders, 1994, 152-182pp.

Okuda, K and The Liver cancer study group of Japan. 1980 “Primary liver cancers in Japan”. Cancer, 45: 2663-2669.

Habibullah, C.M. et al. 1981 “Primary liver cell carcinoma – A study of 50 cases”. J Asso Phys Ind, 29: 921-925.

Rustugi, V.K. 1987 “Hepatic Carcinoma”. Gastroenterol Clin North Am, 16 (4).

Clinico Pathological Study of Leprosy in Northern Karnataka

Abstract Views :373 | PDF Views:0

Authors

Shadakshari Gadigi ¹, Chetana.S. Gadigi ², V. Vijayanath ³, Venkatesh M. Patil ⁴, Rajeshwari R. Surpur ⁵, M. R. Anitha ⁶

Affiliations
1 Department of Pathology, Vijayanagar Institute of Medical Sciences, Bellary, Karnataka, IN
2 Department of Dentistry, Vijayanagar Institute of Medical Science, Bellary, Karnataka, IN
3 Department of Forensic Medicine & Toxicology, S.S.Institute of Medical Sciences & Research Centre Davangere, Karnataka, IN
4 Department of Pharmacology, S.S.Institute of Medical Sciences & Research Centre Davangere, Karnataka, IN
5 Department of Microbiology, S.S.Institute of Medical Sciences & Research Centre Davangere, Karnataka, IN
6 Department of Anatomy, S.S.Institute of Medical Sciences & Research Centre Davangere, Karnataka, IN

Source

Indian Journal of Public Health Research & Development, Vol 3, No 3 (2012), Pagination: 165-168

Abstract

Leprosy continues to be a public health problem in India. Cases were selected regardless of their age, sex, religion, occupation and socio economic status. Pathological examination helps in confirming the clinical diagnosis. Clinically exact typing of leprosy is difficult and even slit-skin smear yields poor results. Majority of the cases were seen in second and third decade. Patients of both sexes were affected and it was more in males than in females. Patients from different religions were affected among these most of them belonged to Hindu religion.

Keywords

Leprosy, Histopathology, Diagnosis

Full Text

References

Guha P K et al. age of onset of leprosy. Leprosy in India 1981; 53(1); 83-87.

Seghal V N et al. slit skin smear in leprosy. International Journal of Dermatology 1990; 29; 9-16.

Chaturvedi R M, Epidemiological study of leprosy in Malwani Suburb of Bombay, Leprosy Review,1988,59; 113-120.

Kar P K et al, A clinic Pathological study of macular lesions in leprosy, Indian Journal of Leprosy,1994,66(4);435-442.

Verma O P et al. some epidemiological features of leprosy in a rural area in Hoogly district in India 1976;48(4);371-381.

Nadkarni N S et al, Significance of histopathological classification in leprosy, original article, Indian Journal of Leprosy 1999,71(3); 325-332.

Shenoi S D et al, Correlation of clinical and histopathological features in untreated macular lesions of leprosy- A study of 100 cases, Indian Journal of Leprosy. April 1988,(60(2),202-205.

Transgenic Animals and Drug Development: a Review

Abstract Views :222 | PDF Views:0

Authors

Venkatesh M. Patil ¹, Santosh N. Kugali ², Rajeshwari Surpur ³, S. A. Dhanalaxmi ⁴, M. R. Anitha ⁵, V Vijayanath ⁶

Affiliations
1 Dept. of Pharmacology, S.S Institute of Medical Sciences and Research Centre, Davangere 577005 Karnataka, IN
2 Department of Pharmacology, M.S. Ramaiah Medical College, Bangalore, IN
3 Dept. of Microbiology, Sri Devraj Urs Medical College, Karnataka, IN
4 Department of Microbiology, Sri Devraj Urs Medical College, Karnataka, IN
5 Dept. of Anatomy, S.S. Institute of Medical Sciences, Karnataka, IN
6 Dept. of Forensic Medicine, S.S. Institute of Medical Sciences, Karnataka, IN

Source

Indian Journal of Public Health Research & Development, Vol 2, No 1 (2011), Pagination: 106-109

Abstract

Pharmaceutical companies face the challenge that only ten percent of compounds tested in clinical trials eventually make it to the market and out of these, only a few will succeed to generate profit. Utilization of genetically altered animals (transgenic animals) in the pharmaceutical industry provides important insights into the function and interaction of particular gene products. Now, with the help of advanced technology numerous transgenic animals have been produced. The advent of transgenic animals has influenced the attrition rate in pharmaceutical research and development by increasing the quality of both targets and compounds. As with any experimental animal model, transgenic animals also have certain limitations but still they provide a powerful tool for the advancement of drugs in the pharmaceutical industry.

Keywords

Animals, Experiment, Drug

Full Text

References

Luthra PM, Singh J, Kumar R, Singh S. Role of Geneknockout Strategy in New drug Discovery. In: Kohli K, Gupta M, Tejwani S editors. Contemporary Perspectives on Clinical Pharmacotherapeutics. Elsevier, 2006:124-144.

Paigen K, Eppig JT. A mouse phenome project. Mamm. Genome, 2000, 11: 715-717.

Marks CL. Animal Models for Human Diseases: Is There a Future Without Them? The Journal of Nuclear Medicine Dec 2006, 47(12):50N-51N.

Jaenisch R, Mintz B. Simian virus 40 DNA sequences in DNA of healthy adult mice derived from preimplatation blastocysts injected with viral DNA. Proc. Natl. Acad. Sci. USA 1974, 71:1250-1254.

Palmiter RD, Brinster RL, Hammer RE, et al. Dramatic growth of mice that develop from eggs microinjected with metallothionein-growth hormone fusion genes. Nature 1982, 300:611-615.

Palmiter RD, Norstedt G, Gelinas RE, Hammer RE, Brinster RL. Metallothionein-human GH fusion genes stimulate growth of mice. Science 1983, 222: 809-814.

Thomas KR, Capecchi MR. Site-directed mutagenesis by gene targeting in mouse embryo-derived stem cells. Cell 1987; 51(3):503-512.

Misra RP, Duncan SA. Gene targeting in the mouse. Endocrine Dec 2002.19(3):229-238.

Gulezian D, Kram DJ, McCollough B, et al. Use of transgenic animals for carcinogenicity testing: Considerations and Impications for risk assessment. Toxicologic Pathology 2000; 28(3):482-499.

Picciotto MR, Wickman K. Using knockout and transgenic mice to study neurophysiology and behaviour. Physiological Reviews Oct 1998;78(4):1131- 1155.

Bowers BJ. Applications of transgenic and knockout mice in alcohol research. Alcohol research & Health 2000; 24(3):175-183.

Lim KI, Dumenco LL, Yun J. et al. High level regulated expression of the chimeric P-enolpyruvate carboxykinase gene in transgenic mice. Cancer Res 1990; 50:1701-1708.

Gossen M, Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc. Natl Acad Sci.USA 1992; 89:5547- 5551.

Sauer B, Henderson N. Site specific DNA recombination in mammalian cells by the Cre recombinase of bacteriophage P1. Proc. Natl Acad Sci. USA 1988; 85:5166-5170.

Folkesson R, Winbald B, Benedikz E. Alzheimer transgenic models. Curr Opin Psychiatry 2002; 15:433- 439.

Gupta SK. Drug Screening Methods 2004; Jaypee Publishers, New Delhi: 97-99.

Deltour L et al. Journal of Biochemistry 1999; 274:16796-16801.

Hodge CW, Mehmert KK, Kelley SP et al. Supersensitivity to allosteric GABAA receptor modulators and alcohol in mice lacking PKCå. Nature Neuroscience 1999;2:997-1002.

Powell-Braxton L, Veniant M, Latvala RD et al. A mouse model of human familial hypercholesterolemia: markedly elevated LDL and severe atheroscelrosis on a low fat chow diet. Nat Med 1998; 4:934-938.

Coleman DL. Obese and diabetes, two mutant genes causing diabetes-obesity syndromes in mice. Diabetologia 1978; 14:141-148.

Peterson RG, Shaw WN, Neel M-A et al. Zucker diabetic fatty rat as a model for noninsulin-dependent diabetes mellitus. ILAR News 1990; 32:16-19.

Thurlby PL, Trayhurn P. The development of obesity in preweanling (ob/ob) mice. Br J Nutr 1978; 39:397-402.

Crofford OB, Davis CK Jr. Growth characteristics, glucose tolerance and insulin sensitivity of New Zealand Obese mice. Metabolism 1965; 14:271-280.

Ghosh MN. Fundamentals of experimental pharmacology 3rd edn. Hilton & Company publishers, Kolkata 2005:8-9.

Mockrin SC, Dzau VJ, Gross KW, Horan MJ. Transgenic animals new approaches to hypertension research. Hypertension 1991; 17(3):394-399.

Rudmann DG, Durham SK. Utilization of genetically altered animals in the Pharmaceutical industry. Toxicologic Pathology 1999; 27(1):111-114.

Srinivasan K, Ramarao P. Animal models in type-2 diabetes research: An overview. Ind J Med Res, mar 2007; 125:451-472.

Internet resource obtained from URL: http:// www.jax.org/resources/documents/imr/ 29. Internet resource obtained from URL: http:// tbase.jax.org.

Username
Password
Remember me